Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
OKYO Pharma Limited - Ordinary Shares
(NQ:
OKYO
)
0.9800
-0.2700 (-21.60%)
Streaming Delayed Price
Updated: 3:57 PM EDT, Jul 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about OKYO Pharma Limited - Ordinary Shares
< Previous
1
2
3
4
5
6
7
Next >
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
July 11, 2024
Via
Benzinga
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
July 11, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
July 10, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Participation in May 2024 Investor Conferences
May 08, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
April 30, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
April 08, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
April 02, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
March 25, 2024
Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today’s pre-market trading following fourth-quarter results.
Via
Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 25, 2024
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
Via
Benzinga
Relief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage Study
March 22, 2024
Latest findings from OKYO Pharma's Phase 2 trial on OK-101 for dry eye disease. Significant reductions in ocular pain, improved Tear Film Break-Up Time, and symptomatic relief were observed....
Via
Benzinga
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
March 22, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
March 21, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
March 20, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
March 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 12, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 09, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 09, 2024
Via
Benzinga
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
February 09, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
January 31, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
January 08, 2024
Via
Benzinga
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
January 08, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
January 05, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
December 04, 2023
Top-line Efficacy and Safety Data on Track for Release in December 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction
October 31, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Dow Rebounds, Still Below Fair Value
October 09, 2023
The Israeli-Palestinian conflict is in focus worldwide, after erupting into a deadly war over the weekend.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
October 09, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
October 05, 2023
Via
Benzinga
Dry Eye Disease Affects Around 50M Americans, OKYO Pharma's Candidate Shows Safety In Mid-Stage Study
October 05, 2023
OKYO Pharma Limited (NASDAQ: OKYO) announced that its first drug candidate, OK-101, presently in a 240-patient phase 2 trial in patients with dry eye disease (DED) is currently showing a positive...
Via
Benzinga
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
October 05, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
October 05, 2023
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.